Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus CEPHRADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus CEPHRADINE.
CEFEPIME IN PLASTIC CONTAINER vs CEPHRADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
Cephradine is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
250-500 mg orally every 6 hours; 500 mg to 1 g intramuscularly or intravenously every 6 hours. Maximum: 4 g/day.
None Documented
None Documented
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
Terminal elimination half-life 0.5–1.5 hours (normal renal function); prolonged to 6–15 hours in severe renal impairment (CrCl <10 mL/min).
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Primarily renal (≥90% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<10%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic